Literature DB >> 19297501

Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G.

Guylaine Haché1, Truus E M Abbink, Ben Berkhout, Reuben S Harris.   

Abstract

APOBEC3G restricts Vif-deficient human immunodeficiency virus type 1 (HIV-1) by deaminating viral cDNA cytosines to uracils. This promutagenic activity is counteracted by HIV-1 Vif, which is a natural APOBEC3G antagonist. However, we previously reported that Vif-deficient HIV-1 could evolve resistance to APOBEC3G by a novel mechanism requiring an A200-to-C/T transition mutation and Vpr inactivation. A pyrimidine at nucleotide 200 in the untranslated leader region contributed to resistance by increasing virus particle production, which resulted in fewer APOBEC3G molecules per particle. Here we show that the A200-to-C/T mutation functions posttranscriptionally by inactivating an upstream start codon, which in turn enables optimal viral mRNA translation from canonical start codons.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19297501      PMCID: PMC2681989          DOI: 10.1128/JVI.00045-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.

Authors:  Andrew Mehle; Bettina Strack; Petronela Ancuta; Chengsheng Zhang; Mark McPike; Dana Gabuzda
Journal:  J Biol Chem       Date:  2003-12-13       Impact factor: 5.157

2.  Mechanism of translation of monocistronic and multicistronic human immunodeficiency virus type 1 mRNAs.

Authors:  S Schwartz; B K Felber; G N Pavlakis
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

Review 3.  Structure and function of the human immunodeficiency virus leader RNA.

Authors:  B Berkhout
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1996

4.  Sequence variation of the human immunodeficiency virus primer-binding site suggests the use of an alternative tRNA(Lys) molecule in reverse transcription.

Authors:  A T Das; B Klaver; B Berkhout
Journal:  J Gen Virol       Date:  1997-04       Impact factor: 3.891

5.  A new reporter cell line to monitor HIV infection and drug susceptibility in vitro.

Authors:  A Gervaix; D West; L M Leoni; D D Richman; F Wong-Staal; J Corbeil
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

6.  Reduced replication of human immunodeficiency virus type 1 mutants that use reverse transcription primers other than the natural tRNA(3Lys).

Authors:  A T Das; B Klaver; B Berkhout
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

7.  The human immunodeficiency virus type 1 5' packaging signal structure affects translation but does not function as an internal ribosome entry site structure.

Authors:  G Miele; A Mouland; G P Harrison; E Cohen; A M Lever
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

8.  Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.

Authors:  Bindong Liu; Xianghui Yu; Kun Luo; Yunkai Yu; Xiao-Fang Yu
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.

Authors:  Mariana Marin; Kristine M Rose; Susan L Kozak; David Kabat
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

10.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.

Authors:  Ann M Sheehy; Nathan C Gaddis; Michael H Malim
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

View more
  18 in total

Review 1.  HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms.

Authors:  Atze T Das; Ben Berkhout
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-06-27       Impact factor: 6.237

2.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

3.  Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors.

Authors:  Judd F Hultquist; Mawuena Binka; Rebecca S LaRue; Viviana Simon; Reuben S Harris
Journal:  J Virol       Date:  2011-12-28       Impact factor: 5.103

Review 4.  The restriction factors of human immunodeficiency virus.

Authors:  Reuben S Harris; Judd F Hultquist; David T Evans
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

5.  Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.

Authors:  John S Albin; William L Brown; Reuben S Harris
Journal:  Virology       Date:  2013-12-20       Impact factor: 3.616

6.  Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.

Authors:  Tayyba T Baig; Yuqing Feng; Linda Chelico
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

7.  Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.

Authors:  John S Albin; Guylaine Haché; Judd F Hultquist; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

8.  Long-term passage of Vif-null HIV-1 in CD4+ T cells expressing sub-lethal levels of APOBEC proteins fails to develop APOBEC resistance.

Authors:  Eri Miyagi; Sandra Kao; Miyoshi Fumitaka; Alicia Buckler-White; Ron Plishka; Klaus Strebel
Journal:  Virology       Date:  2017-01-25       Impact factor: 3.616

9.  The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches.

Authors:  Christopher Richards; John S Albin; Özlem Demir; Nadine M Shaban; Elizabeth M Luengas; Allison M Land; Brett D Anderson; John R Holten; John S Anderson; Daniel A Harki; Rommie E Amaro; Reuben S Harris
Journal:  Cell Rep       Date:  2015-11-25       Impact factor: 9.423

10.  Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice.

Authors:  Matthew M Hernandez; Audrey Fahrny; Ravi Sachidanandam; Roberto F Speck; Viviana Simon; Anitha Jayaprakash; Gustavo Gers-Huber; Marsha Dillon-White; Annette Audigé; Lubbertus C F Mulder
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.